Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2022 | Amyloidosis Sessions: Highlights from ISA 2022

Morie Gertz and Vaishali Sanchorawala • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab

Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session a discussion from the 18th Meeting of the International Society of Amyloidosis (ISA) with leading experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, who share their highlights in amyloidosis from the meeting.

More from Morie Gertz

Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz et al. • 21 Nov 2022
The role of allogeneic transplantation in patients with multiple myeloma
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz et al. • 21 Nov 2022
The importance of identifying AH amyloidosis in patients with normal free light chain levels
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz et al. • 21 Nov 2022
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz et al. • 21 Nov 2022

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Morie Gertz et al. • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Morie Gertz et al. • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Morie Gertz et al. • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Amyloidosis Sessions: Highlights from ASH 2024
Morie Gertz et al. • 8 Dec 2024

Related Videos

Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Morie Gertz et al. • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Morie Gertz et al. • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Morie Gertz et al. • 8 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Morie Gertz et al. • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals